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accumulation  of  NOTCH1  intracellular  domain  (NICD)  and  prolong
signaling.  These  mutations  associate  with  a  more  aggressive  disease
compared  withto  wild-type  (WT)  CLL.  In  this  work  we  demonstrate  a
bidirectional  functional  relationship  between  NOTCH1  and  the  B  cell
receptor  (BCR)  pathways.  By  using  highly  homogeneous  cohorts  of
primary CLL cells, activation of NOTCH1 is shown to increase expression
of surface IgM, as well as LYN, BTK, and BLNK, ultimately enhancing BCR
signaling responses, including global mRNA translation. Upon BCR cross
-linking, NOTCH1 itself is actively translated and increased on cell surface.
Furthermore, BCR ligation induces calcium mobilization that can facilitate
ligand-independent  NOTCH1 activation.  These  data  suggest  that  the  two
pathways are functionally linked, providing a rationale for dual inhibition
strategies.  Consistently,  addition  of  the  γ-secretase  inhibitor  DAPT  to
ibrutinib significantly potentiates its effects, both in vitroin vitro  and in a
short-term  patient-derived  xenograft  model.  While  this  observation  may
find limited applications in the CLL field, it is more relevant for Richter’s
Syndrome (RS) management, where very few successful therapeutic options
exist.  Treatment  of  RS-patient-derived  xenografts  (RS-PDX)  with  the




NOTCH1 is a surface protein and ligand-activated transcription regulator that
controls gene expression directly, by recruiting a transcription complex, and
indirectly, by affecting a complex nuclear balance that involves both
transcription activators (MAML and p300) and inhibitors (HDAC1/2 and
SPEN) [1]. NOTCH1 represents the most commonly mutated gene in patients
with chronic lymphocytic leukemia (CLL) [2]. Prevalence is ~10% at
diagnosis, increasing in high-risk patients and affecting one-third of CLLs
transforming to a diffuse large B-cell lymphoma (Richter’s syndrome, RS) [3,
4]. Two main mutation hot spots were identified: a two-nucleotide deletion in
exon 34, which leads to the generation of a premature STOP codon and a
splice variant in the 3′ UTR. Both mutations generate a truncated protein
lacking the PEST domain that regulates NOTCH1 ubiquitination and
degradation [5, 6]. The absence of the PEST domain prolongs the half-life of
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the active NOTCH1-intracellular domain (NICD) resulting in a quantitative
modulation of the transcriptional program under the direct and indirect control
of NOTCH1. Our previous data highlighted proliferation and chemotaxis as
the two most affected cellular processes. The presence of a longer-lasting
mutated NICD results in a decreased availability of RBPJ, an NICD binding
protein, for the HDACs, which in turn complex with DNA methyl
transferases. The subtle modulation in gene expression can significantly affect
cellular responses to chemokines, and particularly to CCL19, increasing
homing of CLL cells to lymphoid organs, where the proliferative core of the
disease is hosted [7, 8, 9]. In the tumor-friendly environment of the
proliferation center, CLL cells receive signals from the B cell receptor (BCR),
which controls genetic programs resulting in altered balance between
proliferation and death [10], metabolic adaptation [11], and chemokine
secretion [12]. Importantly, one of the mechanisms of action of ibrutinib, a
Btk inhibitor yielding significant clinical responses in patients, is to cause
release of leukemic cells from peripheral lymphoid organs into the blood,
where they are less protected and likely more prone to apoptosis [13, 14, 15].
For these reasons, the question at the base of this paper is whether there is a
functional cooperation between NOTCH1 and the BCR in CLL patients and
whether it may be therapeutically relevant to target both pathways.
AQ3
Peripheral blood samples from CLL patients were obtained after informed
consent, in accordance with Institutional Guidelines and the Declaration of
Helsinki. We examined a cohort of 21 NOTCH1-mutated (M) and 23
NOTCH1-WT samples. All samples carried unmutated immunoglobulin
heavy-chain variable region (IGHV-UM) genes [16, 17] and had a normal
FISH profile or a 13q14 deletion as the sole abnormality. A cut-off of ≥30%
variant allele frequency (VAF) was applied to restrict analyses to clonal
NOTCH1-M samples (Table 1). Analyses were performed either immediately
after thawing cells (+1-h recovery) or after 16-h recovery from anergy
resulting from prior antigen stimulation in vivo in vivo [18]. This second time
point was the best window to discriminate between NOTCH1-M- and -WT-
dependent effects [7]. In fact, while NOTCH1 activation in the absence of
stimuli is rapidly lost in WT samples it still persists in -M cells.
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UM 100 del11;del13 87.70
2 ID425 >30% UM 100 del13 95.4
3 ID283 >30% UM 100 del13 98.1
4 ID982 >30% UM 100 del13 89.2
5 ID233 >30% UM 98.3 del13 88.5
6 PMN246 >30% UM 99.60 del13 97.6
7 ID561 >30% UM 100 del13 87.1
8 PMN336 >30% UM 100 Normal 93.5
9 PMN209 >30% UM 100 del13 94
10 GML064 >30% UM 100 del13 94
11 ID959 >30% UM 100 Normal 86.6
12 ID114 >30% UM 100 Normal 93.8
13 ID1318 >30% UM 100 Normal 93.30
14 PMN150 >30% UM 99 Normal 88.5
15 GML120 >30% UM 98.8 Normal 93.6
16 PMN236 >30% UM 100 Normal 95.40
17 TRN245 >30% UM 100 Normal 97.90
18 PMN335 >30% UM 100 Normal 86.60
19 TRN257 >30% UM 100 Normal 85.5
20 GML068 >30% UM 100 del13 88.2
Clinical and molecular features of the samples included in this study. Asterisks mark d
VAF variant allele frequency, UM unmutated, y years, UnTX untreated Please add the f













Clinical and molecular features of the samples included in this study. Asterisks mark d
VAF variant allele frequency, UM unmutated, y years, UnTX untreated Please add the f
TTFT time to first treatment
OS overall survival
21 PMN200 >30% UM 100 Normal 90
22 ID758 <1% UM 100 del13;del11 96.9
23 PMN116 <1% UM 100 del13 96.4
24 ID148 <1% UM 100 del13 93.5
25 ID1153 <1% UM 100 del13 87.5
26 ID1173 <1% UM 100 del13 96.1
27 ID1178 <1% UM 98.9 del13 97.2
28 ID262 <1% UM 99.2 del13 97
29 ID780 <1% UM 100 del13 98
30 ID288 <1% UM 100 del13 90.5
31 PMN239 <1% UM 98.5 del13 97.6
32 PMN132 <1% UM 98.2 del13 98.4
33 PMN306 <1% UM 100 del13 98.6
34 PMN315 <1% UM 100 Normal 91.6
35 PMN106 <1% UM 100 del13;del11 85
36 ID763 <1% UM 99.7 Normal 97.3
37 ID1195 <1% UM 100 Normal 96.6
38 ID1368 <1% UM 100 Normal 94.50
39 TRN228 <1% UM 100 Normal 98.6
40 NPL274 <1% UM 100 del13 98.5
41 GML125 <1% UM 100 del13 94
42 PMN217 <1% UM 100 del13 97
43 GML077 <1% UM 100 Normal 98
44 PMN337 <1% UM 100 del13 89
+ +
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A complete list of reagents and antibodies is provided in Supplementary
Information (SI).
Ca  fluxes were measured using the Fluo-3 AM calcium indicator
(Thermofisher, Monza, Italy), as described [17]. Samples were acquired using
a FACSCantoII (BD Biosciences, Milan, Italy) and analyzed with FlowJo
v9.7.6 (FlowJo, Ashland, OR). Percent Ca  mobilization was calculated as
[peak (all events)—mean Y (unstimulated cells)/%CD19  cells] × 100, where
%CD19  cells was the percentage of CD19  cells in the live lymphocyte gate
of the test sample.
Phosphorylation of downstream players in BCR signaling cascade was
evaluated using a Phosflow assay [19]. CLL cells (10 ) were stimulated with
α-IgM [5 µg/ml, F(ab) , 10 min]. Fixed and permeabilized cells were stained
with antibodies listed in SI. Where indicated, cells were pretreated with
ibrutinib and/or DAPT.
AQ7
Global mRNA translation was evaluated using the Click-iT™ Plus OPP
Alexa-Fluor-647 Protein Synthesis Assay Kit (Invitrogen, Thermofisher) [20].
Full details in SI.
Ribosomes were separated into polysomal and subpolysomal fractions using a
sucrose density gradient centrifugation [21]. Full details in SI.
Primary CLL cells and RS cells were intravenously (i.v.) injected in
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vivoin vivo experiments were approved by the Italian Ministry of Health
(Authorization n.12/2016-PR). Full details in SI.
Methods fully described in the SI include: EDTA stimulation, RNA extraction
and qRT-PCR, western blot, immunohistochemistry, apoptosis assay, in vivoin
vivo experiments.
Statistical analyses were performed with GraphPad v6 (GraphPad Software
Inc, La Jolla, CA, USA). Data are expressed as fold change over unstimulated
or untreated cells (FC/NT) to highlight modulation induced by α-IgM and/or
treatments. In the figures, data are presented as mean ± SD. The Mann–
Whitney or Wilcoxon matched-pairs signed rank test was used to determine
statistical significance. In the case of grouped analyses, the two-way ANOVA
test was preferred. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Analysis of drug combination effects was performed by calculating a
Combination Index (CI) based on the Bliss Independence model, which
assumes that the examined drugs act independently on different sites of
actions, but each contributes to a common result [22]. CI was calculated as:
Where E , E  and E  indicate the effects of either drug used as single agents
or drug combination effects, respectively. A CI value <1 indicates synergism,
>1 indicates antagonism, while values around 1 indicate an additive effect.
We first tested whether activation of NOTCH1 pathway impacted on the
expression of BCR signaling members. To do this, we artificially induced
NOTCH1 cleavage on primary CLL cells using EDTA that releases surface
NOTCH receptors in a ligand-independent way [23]. We found that short
EDTA treatment (15 min) was sufficient to trigger NOTCH1 activation in -M
but not in -WT samples, as indicated by mRNA levels of HES1 and DTX1
A B AB
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(Fig. 1a). Under these conditions, we observed significantly increased surface
IgM (sIgM) levels in NOTCH1-M samples compared with the counterpart
(Fig. 1b). No differences in the background staining, i.e., isotype controls
(I.C), were observed after EDTA treatment (not shown). Furthermore,
NOTCH1 activation led to increased transcription of LYN, BTK and BLNK
(Fig. 1c), consistent with recent observations highlighting a NOTCH1-
regulated BCR gene signature in CLL [24]. Accordingly, pretreatment with
the γ-secretase inhibitor (DAPT), which prevents NICD cleavage, completely
abrogated these effects (Fig. 1a–c). When maintaining EDTA treatment for 6 
h, we obtained appreciable levels of NOTCH1 activation also in -WT CLL
samples, leveling differences with -M samples (Supplementary Fig. 1a).
Prolonged EDTA stimulation increased sIgM levels, as well as LYN, BTK, and
BLNK expression, independently of NOTCH1 mutational status, recapitulating
the effects that were already visible in -M samples in more stringent
experimental conditions (Supplementary Fig. 1b, c). The inference of these
results is twofold: on one side, they indicate that NOTCH1 might directly
modulate BCR signaling by regulating the expression of multiple elements in
its signaling cascade; on the other side, they suggest the existence of a
threshold of activation required to observe NOTCH1-mediated effects and
that weaker or transient stimuli are sufficient to trigger signaling in -M
samples, but not in -WT, likely due to NICD accumulation as a consequence
of the mutation [7].
Fig. 1
Activation of NOTCH1 signaling increases expression of the BCR and related
genes.  a  Short-term  EDTA  treatment  (15 min)  of  primary  CLL  samples
increases expression of HES1 and DTX1,  selected as representative NOTCH1
target genes, in NOTCH1-M samples, but not in NOTCH1-WT. Analyses were
performed by treating cells with 5 mM EDTA for 15 min and waiting 2 h after
EDTA wash out.  Treatment  with the γ-  secretase inhibitor  DAPT completely
abolishes HES1  and DTX1  induction.  A total  of  7  cases  from each category
were analyzed.  b  Representative  flow cytometry profiles  of  sIgM expression
following the indicated treatments. A representative case in the NOTCH1-WT
and -M categories  is  shown.  The plot  on the  right  shows cumulative  results
obtained from the eight patients analyzed. The histogram below flow cytometry
profiles shows the selective increase in sIgM expression in NOTCH1-M vs -WT
cases,  following  treatment  with  EDTA,  expressed  as  fold  change  over
unstimulated cells (FC/NT). Where indicated, cells were pretreated with DAPT,
which was maintained during EDTA incubation and in the following 6 h and
which completely prevented sIgM levels increase. sIgM levels were analyzed 6 
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h after  EDTA wash out.  c  RT-PCR data  showing expression  levels  of  genes
belonging  to  the  BCR pathway,  including  LYN,  BTK,  and  BLNK.  Increased
expression is only observed in NOTCH1NOTCH1-M cases and is completely
prevented by DAPT administration. Seven different primary samples for each
category were analyzed. Analyses were performed by treating cells with 5 mM
EDTA for 15 min and waiting 2 h after EDTA wash out. RE: relative expression
We then compared baseline expression and signaling through sIgM in our
cohort of IGHV-UM selected CLL samples. Flow cytometry analysis,
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performed shortly after thawing to recapitulate in vivo in vivo conditions,
indicated that sIgM levels were variable across samples in both subsets.
Nevertheless, NOTCH1-M cells showed significantly higher sIgM compared
withto the WT counterpart (Fig. 2a, left panel). Importantly, stratification of
samples according to surface levels of CD38 and CD49d (Fig. 2a, middle and
right panels), to ZAP70 expression or Rai classification of disease stage
(Supplementary Fig. 2), failed to reveal significant associations.
Fig. 2
NOTCH1-M  cases  show  constitutively  higher  levels  of  sIgM  and  are  more
responsive to IgM cross -linking. a sIgM levels determined by flow cytometry
immediately  after  thawing  in  a  cohort  of  35  CLL  patients,  17  of  which
harboring NOTCH1-M. Results indicate that the only significant association is
between NOTCH1 mutational status and sIgM levels, while CD38 and CD49d
surface expression are not significantly associated. b  Left panel. NOTCH1-M
primary cells mobilize significantly more Ca  ions in response to BCR ligation
signaling compared with the counterpart. Right panel. Regression line showing
a  direct  relationship  between  sIgM  levels  and  intracellular  Ca  fluxes  in
response to BCR cross-  linking. Each dot identifies a different primary case.
NOTCH1-M cases are in red. c BCR cross -linking in NOTCH1-M cases results
in  higher  signaling  performances  compared  with  NOTCH1-WT  cases,  as
determined  by  Phosphflow  assay.  Specific  readouts  include  pBTK  (top),
pPLCγ2 (middle) and pERK1/2 (bottom) evaluated 16 h after thawing to allow
complete  recovery  from  in  vivoin  vivo  anergy.  Representative  profiles  for
NOTCH1-M and -WT cases are reported on the left, while histogram bars show
cumulative data. The effects of ibrutinib (Ib), DAPT and their combination is
shown.  Red  bars  identify  NOTCH1-M  samples.  Star  marks  above  each  bar
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Consistently, NOTCH1-M CLLs were also significantly more responsive to
sIgM engagement than -WT cells, as witnessed by intracellular calcium
release in response to α-IgM triggering of BCR after 1 h (Supplementary
Fig. 2B) and 16 h (Fig. 2b, left panel), and by the robust correlation between
sIgM levels and calcium mobilization in our cohort (Fig. 2b right panel). We
next compared critical responses occurring downstream to BCR signaling
activation in the NOTCH1-WT and -M sample subsets. BCR engagement
triggers a phosphorylation cascade of mediators ultimately leading to the
activation of MAPK and NFκB signaling [25, 26]. Upon short soluble α-IgM
stimulation (10 min), NOTCH1-M samples showed significantly increased
phosphorylation of BTK, PLCγ2, and ERK compared withto -WT, as
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evaluated by a Phosflow assay. Pretreatment with ibrutinib efficiently
prevented the phosphorylation cascade in both subsets, whereas blocking
NOTCH1 activation with DAPT had no measurable effects, indicating that
NOTCH1 itself does not directly regulate early events downstream to BCR
ligation (Fig. 2c).
Genetic reprogramming was evaluated after 24 h stimulation with plate-bound
α-IgM, to induce persistent activation of BCR signaling [16]. mRNA levels of
MYC and CCL3 were analyzed as representative BCR target genes [27, 28,
29], and were robustly increased upon α-IgM stimulation in both NOTCH1-
WT and -M samples (Fig. 3a). However, both genes were significantly more
induced in the NOTCH1-M CLL subset. Interestingly, BCR stimulation in the
presence of DAPT significantly restricted MYC and CCL3 induction acting
selectively in -M samples and reducing, at least in part, the difference
between the two subsets. Furthermore, when used in combination, DAPT
enhanced the effects of ibrutinib in both NOTCH1-WT and -M samples
(Fig. 3a), indicating that the two pathways cooperate independently of the
mutation and that sustained NOTCH1 activation, as in the case of PEST
domain mutations, may confer further advantage to CLL cells.
Fig. 3
NOTCH1-M cases show higher levels of MYCMYC and CCL3CCL3 induction
compared  with  NOTCH1NOTCH1-WT in  response  to  IgM cross  -linking.  a
Histograms  show  MYC  (left)  or  CCL3  (right)  RNA  levels  in  NOTCH1-M
compared with NOTCH1-WT cases. Data are represented as fold change over
the  untreated  condition  (FC/NT).  Ibrutinib  (Ib),  DAPT or  their  combination
were added to the cultures where indicated. Star marks above each bar indicate
significance  referred  to  corresponding  (paired)  α-IgM  NT  condition.  (RE:
relative expression.) (b, (left panel) Western blot showing c-MYC expression
levels before and after IgM cross -linking in representative NOTCH1-M or -WT
cases. Histogram plots reporting intensity of the c-MYC bands in 5 NOTCH1-M
or -WT cases at 6-h (middle panel) and at 24-h stimulations (right panel). Band
intensities were measured using ImageJ and are shown as fold change over the
band referring to  unstimulated cells  (FC/NS).  Red bars  identify NOTCH1-M
samples
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In line with RT-PCR data, MYC was strongly induced at the protein level
upon BCR ligation and significantly more in the NOTCH1-M subset (Fig. 3b).
MYC induction was already evident after 6 h stimulation, indicating that it is
an early event in BCR signaling.
BCR signaling is considered the driving force for CLL cell proliferation and
survival and operates through the modulation of protein translation [20],
which represents the cell core-power. We compared global mRNA translation
in NOTCH1-WT and -M samples after 24 h BCR engagement with bead-
bound α-IgM, to induce sustained signaling by preventing receptor
internalization, similarly to plate-bound α-IgM. Compared withto WT
samples, NOTCH1-M CLLs showed increased BCR-induced global mRNA
translation (Fig. 4a). Ibrutinib alone did not completely shut down translation
in the -M subset, whereas it was sufficient to fully inhibit it in -WT cells.
Interestingly, DAPT also significantly inhibited global mRNA translation in
response to BCR in both subsets, suggesting a major contribution of NOTCH1
pathway. In NOTCH1-M samples, addition of DAPT potentiated the effects of
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ibrutinib alone and decreased mRNA translation levels to those of
unstimulated cells, abrogating the difference with -WT cells (Fig. 4a).
Fig. 4
NOTCH1-M  samples  show  significantly  higher  levels  of  global  mRNA
translation  compared  with  the  NOTCH1-WT  counterparts.  a O-propargyl-
puromycin  (OPP)  labeling  test  show  increased  global  mRNA  translation  in
NOTCH1-M (red) compared with NOTCH1-WT (blue) primary samples. Cells
were treated with plate-bound α-IgM for 24 h, with the indicated drugs added at
the  beginning  of  the  culture.  b  Expression  levels  of  the  elongation  factors
(eIF4G,  eIF3b,  PDCD4,  and  eIF4A)  in  NOTCH1-M  or  -WT  representative
samples. c mRNA expression levels of NPM1 in NOTCH1-M vs NOTCH1-WT
samples treated as indicated. Star marks above each bar indicate significance
referred  to  corresponding  (paired)  α-IgM  NT  condition.  RE:  relative
expression), Ib: ibrutinib.
Translation initiation factors such as eIF4G, eIF4A, and eIF3b were induced
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24 h after stimulation, with NOTCH1-M samples showing a slightly but
consistently more robust effect (Fig. 4b and Supplementary Fig. 3A). In line
with previous data [20], cross-linking of BCR downregulated expression of
PDCD4, a negative regulator of eIF4A [30] (Fig. 4b). At variance with MYC,
levels of eIFs were unmodulated at earlier time points (Supplementary
Fig. 3B-C), corroborating the hypothesis of a direct MYC-dependent
regulation of the translation machinery.
Nucleophosmin1 (NPM1), a nucleolar protein regulating ribosome biogenesis
and therefore taking part to translation [31], was recently pointed out as a
mediator of proliferation and survival in CLL, being overexpressed in
NOTCH1-M samples in a MYC-dependent way [32]. In keeping with these
observations, BCR engagement strongly induced NPM1 transcription
selectively in NOTCH1-M samples with DAPT significantly inhibiting this
effect (Fig. 4c).
We showed that NOTCH1 activation impacts on BCR signaling particularly in
the presence of PEST domain mutations. To explore bidirectional functional
interactions, we asked if BCR-induced translation involved NOTCH1 itself or
its ligands. Polysome profiling confirmed enrichment of NOTCH1 mRNA in
the latest fractions, indicating active translation (Fig. 5a). In contrast, no
enrichment of DLL1 mRNA was observed, suggesting a NOTCH1-restricted
effect (Supplementary Fig. 4A). Consistently, we observed variation in
surface NOTCH1 levels upon BCR cross-linking, but not in DLL1 (Fig. 5b
and Supplementary Fig. 4C, D). Specifically, while NOTCH1-WT samples
showed variable modulation of NOTCH1 expression at the membrane level,
with samples increasing NOTCH1 MFI and others remaining unmodulated,
-M cells were more consistently responsive (Fig. 5b). Ibrutinib significantly
downregulated surface NOTCH1 in both -M and -WT samples, while
treatment with DAPT did not, supporting a BCR-mediated effect (Fig. 5b,
bottom left). Modulation of NOTCH1 occurred specifically at the protein
level, as mRNA expression was modestly increased, more in the -M subset,
but treatment with inhibitors did not result in major alterations of gene
expression, suggesting a post-transcriptional regulation (Supplementary
Fig. 4B). Consistently, stimulation of BCR signaling in the presence of
cycloheximide (CHX), to block protein translation, significantly reduced
NOTCH1 expression, whereas it had no effects on DLL1 surface levels
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(Fig. 5b bottom right and Supplementary Fig. 4C, D). Lastly, downmodulation
of NOTCH1 expression by CHX was not due to perturbation of cell
homeostasis or viability, as NOTCH1 mRNA levels were increased upon CHX
treatment, suggesting either accumulation of untranslated mRNA or even
enhanced transcription to overcome impaired translation (Supplementary
Fig. 4E).
Fig. 5
NOTCH1 expression and activation are induced upon BCR ligation. a Polysome
fractionation profiling show enrichment of NOTCH1 mRNA in fractions 9 and
10,  marking more  active  translation,  upon plate-bound α-IgM stimulation.  b
NOTCH1 MFI  is  consistently  increased  in  NOTCH1-M  samples  at  variance
with  -WT cells.  Cumulative  data  and effects  of  treatments  are  shown in  the
bottom left panel. The presence of CHX significantly impairs α-IgM-mediated
surface  NOTCH1 increase  but  has  no  effect  on  surface  DLL1 (bottom right
panel, CHX: cycloheximide). c DTX1 levels are markedly increased upon BCR
ligation specifically in NOTCH1-M samples. Treatment with ibrutinib (Ib) and
DAPT,  either  alone or  in  combination,  significantly  reduces DTX1  induction
with  drug  combination  showing  the  greatest  inhibition.  Consistent  with  the
effect on NOTCH1 surface levels, CHX strongly prevents DTX1 induction. P
values for M samples are shown. d Stimulation of NOTCH1-M CLL cells with
PMA  and  Ionomycin  (Iono)  for  6 h  induces  NICD  cleavage  and  HES1  and
DTX1  expression. Star marks above each bar indicate significance referred to
corresponding  (paired)  α-IgM  NT  condition.  Results  are  expressed  as  fold
change over unstimulated cells (FC/NT). RE: relative expression.
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Upregulation of NOTCH1 expression was accompanied by activation of the
signaling pathway, specifically in the NOTCH1-M subset. DTX1 and HES1
levels were strongly upregulated upon BCR ligation in -M samples, with both
ibrutinib and DAPT showing efficient inhibition as single agents and
enhanced effects when used in combination (Fig. 5c and Supplementary
Fig. 5). Interestingly, CHX also inhibited DTX1 induction similarly to
NOTCH1 overexpression (Fig. 5c, right panel). In line with NOTCH1
regulating a BCR gene signature, we observed significant upregulation of
BTK, LYN and BLNK in NOTCH1-M samples induced by α-IgM stimulation.
This effect was downmodulated both by ibrutinib and DAPT and was
prevented by CHX, just as DTX1 (Supplementary Fig. 6A–D). As a control,
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neither CCL3 nor MYC levels were downregulated by CHX, being rather
upregulated possibly as a result of mRNA accumulation, thus limiting the
effect to a strictly NOTCH1-dependent gene signature (Supplementary
Fig. 6E).
These results indicate that not only NOTCH1 surface levels are increased
upon BCR signaling, but also that the pathway is activated, suggesting a
ligand-independent NOTCH1 activation, likely involving protein kinase C
(PKC), as recently demonstrated [33]. To test this hypothesis, we stimulated
NOTCH1-M CLL cells with PMA and ionomycin, both alone and in
combination, to activate PKC and Ca  release from intracellular stores,
respectively. We observed that PMA alone efficiently triggered NOTCH1
activation, evaluated both as NICD cleavage and HES1 and DTX1
upregulation, and that addition of ionomycin potentiated the effect (Fig. 5d).
In contrast, ionomycin as a single agent did not result in major modifications
of NOTCH1 activity, suggesting that PKC-mediated activation of ADAM and
γ-secretase is the predominant mechanism and that intracellular calcium
mobilization may further contribute to NOTCH1 activation.
We then asked whether interrupting the crosstalk between BCR and NOTCH1
pathways would affect CLL cell homeostasis. Stimulation of CLL cells with
immobilized α-IgM promoted leukemic cell survival by rescuing them from
spontaneous apoptosis occurring in vitroin vitro, without differences between
NOTCH1-WT and -M samples. As expected, ibrutinib led to a prominent
apoptotic response independently of NOTCH1 mutations, while DAPT
completely abrogated the benefits of BCR triggering without major toxicity
for CLL cells, suggesting that NOTCH1 pathway partly mediates BCR-driven
pro-survival signals. Accordingly, addition of DAPT potentiated ibrutinib
effects, independently of NOTCH1 mutations. Notably, cell viability in
NOTCH1-M samples was significantly more affected by the drug combination
compared withto -WT cells, supporting the hypothesis of an interplay between
the two pathways that is further sustained in the presence of PEST domain
mutations (Fig. 6a). Drug combination analyses revealed a trend toward
synergism between ibrutinib and DAPT in NOTCH1-M samples (CI = 0.87) at
variance with WT cells where responses to dual targeting were similar to the
expected additive effect (CI = 1). In line with flow cytometry data, activation
of PARP and Caspase 3 was maximal in cells treated with drug combination
2+
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(Fig. 6b).
Fig. 6
BCR  and  NOTCH1  pathways  cooperate  in  sustaining  CLL  cell  survival.  a
Representative dot plot of an Annexin V/ Propidium iodide assay to evaluate
apoptosis  of  CLL cells  in  response  to  α-IgM stimulation  in  the  presence  or
absence of the indicated treatment  conditions.  Cumulative data are shown as
histograms in the bottom panel and expressed as fold change of cell viability
compared  with  unstimulated/untreated  cells  (FC/NT).  b  WB  of  PARP1  and
Caspase 3 cleavages in the indicated conditions. Ratio of full length (FL) and
cleaved (CL)  protein  band intensities  is  shown below each  lane.  Star  marks
above each bar indicate significance referred to corresponding (paired) α-IgM
NT condition. c Flow cytometry analysis of CD5 /CD19  cells in the spleen of
NSG mice injected with primary CLL cells (n = 3 samples) and treated with the
indicated  drugs.  Each  spleen  was  divided  in  three  parts  and  each  fragment
dismantled  and  analyzed  independently,  resulting  in  three  measurements  for
each mouse.  Cell  numbers  are  normalized over  100,000 acquired events.  Ib:
ibrutinib.
To confirm in vitroin vitro findings, we explored dual targeting approaches in
short-term CLL-PDX models. Primary cells collected from 3 NOTCH1-M
+ +
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CLL patients of our cohort were i.v. injected in busulfan-primed NSG mice.
Treatment with ibrutinib and DAPT, either as single agents or in combination,
was initiated at day −1 before injection and continued for the following 3
days. After this schedule, mice were euthanized to analyze and compare CLL
cells engraftment in the different treatment arms. Ibrutinib used as single
agent significantly reduced CLL spleen colonization, whereas DAPT alone led
to a modest decrease of CLL cells number. In line with in vitroin vitro results,
drug combination further potentiated ibrutinib effects with a trend toward
synergism (CI = 0.81; Fig. 6c).
Lastly, we asked whether dual inhibition of BCR signaling and NOTCH1
pathway could represent an opportunity for novel treatment strategies in RS, a
fatal complication of CLL which remains drug-orphan. To this aim, we took
advantage of four RS-PDX models recently established by our group [34].
Relevant molecular features of these models are recapitulated in
Supplementary Table 1, full genetic details were previously described [34].
We focused our attention on RS9737 that was the only sample carrying the
c.7541–7542_delCT mutation in NOTCH1NOTCH1 PEST domain and
showing activation of both NOTCH1 and BCR pathways at higher levels than
the other models (Fig. 7a). In vitro In vitro treatment of RS9737 cells revealed
only partial responses to ibrutinib and DAPT as single agents, whereas
synergism of drug combination significantly increased apoptosis (CI = 0.35;
Fig. 7a right panel). Cells were then i.v. injected in NSG mice to evaluate the
effects of treatments on disease dissemination and on survival. Cells were
allowed to engraft for 10 days before daily administration of ibrutinib and
DAPT, either alone or combined (Supplementary Fig. 7A). At the end of the
treatment schedule, mice were either euthanized to compare engraftment in
spleen and bone marrow (BM) or monitored to generate a survival curve.
Compared with vehicle or to ibrutinib and DAPT used as single agents, drug
combination significantly reduced spleen and BM colonization, as
documented macroscopically by measuring spleen size and microscopically
by immunohistochemical analyses or leukemic cells count in both districts
(CI = 0.64 in the spleen, CI = 0.35 in the BM; Fig. 7b). Similar results were
obtained in liver, lung, kidney, brain, and PB (Supplementary Fig. 7B).
Importantly, drug combination also significantly prolonged mice survival
(Fig. 7c). Treatment with ibrutinib or DAPT alone only partially limited RS
growth and spread, with variable responses (Fig. 7b, c).
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Fig. 7
Dual targeting of BCR signaling and NOTCH1 pathway opens the way to novel
treatment options in RS models. a (left panels) WB analysis of expression and
activation of NOTCH1 pathway and BCR signaling in four RS samples grown
in PDX models. RS cells were lysed immediately after collection from PDX to
benefit from previous in vivoin vivo pathways activation. RS9737 was the only
sample carrying the c.7541-7542DelCT mutation in NOTCH1 and showing high
activity  of  both  pathways.  RS9737  also  harbored  a  partial  deletion  of
chromosome 9, thus making mutated NOTCH1  the only allele expressed. For
this  reason,  experiments  were  carried  out  mostly  on  this  sample  (asterisk).
(Right  panel)  RS9737  cell  viability  upon  in  vitro  in  vitro  treatment  with
ibrutinib (Ib) and DAPT either alone or in combination. b Mice treated with the
combination of ibrutinib and DAPT show significantly reduced spleen size as
documented by pictures (top left) and recapitulated by measures (top right) (Veh
vehicle-treated mice). IHC sections of spleens and breastbones (representative
of BM), collected from mice in the different treatment arms, show decreased
anti-CD20 staining in double-treated animals (middle panels). Reduced spleen
and BM colonization is confirmed by flow cytometry analyses of CD45 /CD19
cells  (bottom  panels).  Cell  numbers  are  normalized  over  100,000  acquired
events.  c  Efficacy  of  dual  inhibition  of  BCR  signaling  and  NOTCH1  is
documented  also  by  prolonged  animals’  survival  (mean  survival  with  the
combination 29.75 ± 1.3 days vs. 26.25 ± 0.5 days with ibrutinib vs. 26.75 ± 0.6
days with DAPT vs. 22.5 ± 0.3 days with vehicle)
+ +
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Since the first approval of ibrutinib by the Food and Drug Administration in
February 2012, the therapy of CLL has undergone a revolution, with patients
moving toward chemotherapy-free regimens [35]. The novel drugs interrupt
constitutive BCR signaling, such as Btk and PI3K inhibitors [36] or induce
apoptosis, such as bcl2 inhibitors [37, 38]. The development of resistance in a
minority, but still relevant proportion of patients, has prompted novel efforts
into studying drug alternatives or combinations that may fully eradicate the
disease [39, 40]. In order to do so, it is important to know the hierarchy of
signaling pathways within the CLL cell. This work was undertaken with the
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aim of understanding whether and how BCR and NOTCH1 signaling
pathways interact. Preliminary evidence indicates that genes encoding
elements of BCR signaling are part of a signature directly regulated by
NOTCH1 [24, 41]. Furthermore, evidence in different tumor types suggests
the existence of a NOTCH/PI3K axis that may represent a connection between
NOTCH1 and BCR pathways in B-cell malignancies [42, 43, 44, 45].
For this work, we used only primary patient cells that were carefully selected
in order to avoid confounding factors that may impact on BCR signaling.
While this approach is certainly a limitation as genetic manipulation of
primary cells remains limited, it offers indirect proof of the validity of the
results in a “real-life” situation. We focused on IGHV-UM CLLs for two main
reasons. The first is that the UM subset is more responsive to BCR ligation as
witnessed also by a more aggressive disease with a worse clinical prognosis
[17]. The second is that NOTCH1 mutations are more frequent in IGHVIGHV-
UM samples.
Results demonstrate the existence of a functional loop linking NOTCH1 and
the BCR in CLL cells. We decided to start studying the loop by artificially
activating NOTCH1 using EDTA, which is believed to cause a 3D
conformational modification of the extracellular portion of the molecule,
exposing the cleavage site for ADAM proteases [23]. Under stringent
conditions, i.e., a transient 15 min incubation with EDTA followed by 2–6 h
recovery, we can detect transcriptional activation of targets selectively in
NOTCH1-M samples. Interestingly, these patients also show increased sIgM
expression and transcription of genes that code for integral components of the
BCR pathway, including LYN, BTK, and BLNK. If we open the loop at the
other end, i.e., if we activate the BCR using antibodies, we detect increased
NOTCH1 expression and signaling. Considered together, these two findings
can be explained by hypothesizing (i) that BCR directly controls translation of
NOTCH1 and (ii) that somehow the BCR can also control NOTCH1
activation in a ligand-independent, possibly PKC-dependent, way. The OPP
translation assay confirmed globally increased translation following BCR
activation. While this finding is not novel, the relevant observation is that
there is a markedly higher translation in NOTCH1-M compared with -WT
cases. The finding of mRNA enrichment in polysome fractions marking active
translation confirms that NOTCH1 is among the proteins subjected to this
regulation. Furthermore, the finding that the NOTCH1 ligand DLL1 is not
regulated in this way confirms that the signal is specific and that there are
e.Proofing https://eproofing.springer.com/journals_v2/printpage.php?token=2d...
25 di 33 27/08/2019, 14:27
likely ligand-independent NOTCH1 activation mechanisms. If no ligand is
bound, NOTCH receptors are internalized through endosome vesicles and
either driven to lysosome-mediated degradation or alternatively maintained
into late endosomes and possibly recycled to the membrane, an event
facilitated by DTX1 [46]. It was recently demonstrated that in endosomes
from T lymphocytes, NOTCH1 can be activated upon TCR triggering through
a ligand-independent PKC-dependent mechanism that promotes ADAM- and
γ-secretase-mediated NOTCH1 cleavage [33]. In our context, these
observations imply that activation of the BCR signaling pathway, with
concomitant induction of PKC activation and calcium mobilization, would be
enough to drive NOTCH1 pathway activation, underlining the strong
functional connection between the two pathways (Supplementary Fig. 8). In
this scenario, mutations stabilizing active NOTCH1 might confer an
advantage to leukemic cells, as weak stimuli would be sufficient to trigger
relatively big effects. Mechanistically, one possible explanation is that BCR-
driven PKC-dependent activation of ADAM and γ-secretase results in a
modest NICD cleavage, which is rapidly degraded in the absence of
stabilizing mutations. In contrast, PEST-mutated NICD accumulates because
of inefficient dismantling, amplifying NOTCH1 signaling activation upon
BCR engagement. Consistently, we could appreciate considerable NOTCH1
activation upon triggering of BCR only in samples harboring NOTCH1
mutations.
Our results support the view of a feed-forward loop of functional cooperation
between NOTCH1 and the BCR, where the former has direct effects on IgM
signaling and the latter can induce ligand-independent NOTCH1 activation
further enhancing antiα-IgM responses, remarkably in the presence of
NOTCH1 PEST mutations.
These findings provide the rationale for co-targeting BCR and NOTCH1. In
line with our hypothesis and with recent observations [47], CLL cells in
vitroin vitro die at higher rates in the presence of NOTCH1 and BCR
inhibitors. Notably, the effects of dual inhibition are more prominent in
NOTCH1-M cells likely because the functional cooperation between the BCR
and NOTCH1 is more pronounced in this subset. However, the CLL field is
very crowded, with many novel, effective, and highly safe drugs, that already
offers therapeutic alternatives to ibrutinib-resistant patients, before exploiting
combination strategies. This is not the case for RS, a rare but very often fatal
complication of CLL, with limited therapeutic options beside the CHOP/R-
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CHOP regimens [48]. We recently established four PDX models of RS and
showed that one of them harbors NOTCH1 PEST domain mutation [34].
These cells have a constitutively hyperactive NOTCH1 pathway, with a
prominent band corresponding to the NICD. Intriguingly, they also have the
highest levels of Btk and PI3K activation, suggesting that the BCR-NOTCH1
circuit could be fully functional in these cells. For these reasons, this model
was selected to perform pilot experiments co-targeting the two pathways.
After excluding Btk mutations, we selected ibrutinib and the γ-secretase
inhibitor DAPT to treat these animals. In experiments where all animals were
treated every day for two weeks before evaluating disease spread, mice treated
with the combination of ibrutinib and DAPT had significantly less tumor
burden in every compartment considered. Accordingly, these mice lived
longer than vehicle-treated mice.
In conclusion, our data highlight that NOTCH1 and BCR pathways are
connected in a functional loop, with NOTCH1-M CLL being more responsive
to BCR signaling. Future studies will tell whether this knowledge can be
exploited therapeutically, expanding to nonmutated NOTCH1 activated cases
and particularly in the context of RS, which remains an incurable condition
with limited therapeutic options.
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